{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:53:49Z","timestamp":1778158429612,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The CyberKnife is a robotic stereotactic body radiotherapy (SBRT) system which has shown promising results for many malignances with good efficacy and low toxicity. This study aims to evaluate the response and local control (LC) obtained with CyberKnife in the management of iliac lymph node metastases (ILNM). Twenty-two patients with 27 ILNM were treated by CyberKnife from May 2010 to May 2016. Median follow-up time was 33 months (8\u201397). The complete response, partial response, stable disease and progression disease rates were 37.0%, 48.0%, 7.5% and 7.5% respectively. The 1-, 2-, and 3-year LC rates were all 90.6%, and overall survival rates were 78.8%, 60.6%, and 43.3% respectively. All patients with pelvic pain and ureter obstruction achieved good and fast symptom relief, while leg edema persisted in 2 patients. The general treatment tolerance was acceptable and no severe toxicities were reported. No factors were found correlated with local failure. While overall survival (OS) was better for patients who had received a total dose more than 30\u2009Gy or prior systemic treatment, and whose symptoms were relieved. Taken together, CyberKnife is an effective therapeutic option for ILNM, providing high LC rate and good symptom relief with minimal toxicity.<\/jats:p>","DOI":"10.1038\/srep37987","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T10:06:29Z","timestamp":1480413989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis"],"prefix":"10.1038","volume":"6","author":[{"given":"Zhongqiu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongqing","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,29]]},"reference":[{"key":"BFsrep37987_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1245\/s10434-014-3854-8","volume":"22","author":"MG Niebling","year":"2015","unstructured":"Niebling, M. G. et al. Deep lymph node metastases in the groin significantly affects prognosis, particularly in sentinel node-positive melanoma patients. Ann. Surg Oncol. 22(1), 279\u2013286 (2015).","journal-title":"Ann. Surg Oncol."},{"key":"BFsrep37987_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1245\/s10434-009-0756-2","volume":"17","author":"D Baratti","year":"2010","unstructured":"Baratti, D. et al. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann. Surg Oncol. 17(1), 45\u201353 (2010).","journal-title":"Ann. Surg Oncol."},{"key":"BFsrep37987_CR3","first-page":"69069","volume":"86","author":"A Lopes","year":"2000","unstructured":"Lopes, A., Bezerra, A. L., Serrano, S. V. & Hidalgo, G. S. Iliac nodal metastases from carcinoma of the penis treated surgically. BJU In.t 86(6), 69069\u201369063 (2000).","journal-title":"BJU In.t"},{"key":"BFsrep37987_CR4","first-page":"391","volume":"94","author":"MS Hoffman","year":"1999","unstructured":"Hoffman, M. S., Parsons, M., Gunasekaran, S. & Cavanagh, D. Distal external iliac lymph nodes in early cervical cancer. Obstet Gynecol. 94(3), 391\u2013394 (1999).","journal-title":"Obstet Gynecol."},{"key":"BFsrep37987_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","volume":"26","author":"M Scorsetti","year":"2016","unstructured":"Scorsetti, M. et al. Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer. Breast. 26, 11\u201317 (2016).","journal-title":"Breast."},{"key":"BFsrep37987_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fonc.2015.00185","volume":"5","author":"A Desai","year":"2015","unstructured":"Desai, A. et al. A Retrospective Review of CyberKnife Stereotactic Body Radiotherapy for Adrenal Tumors (Primary and Metastatic): Winthrop University Hospital Experience. Front Oncol. 5, 185 (2015).","journal-title":"Front Oncol."},{"key":"BFsrep37987_CR7","doi-asserted-by":"publisher","first-page":"372","DOI":"10.5582\/ddt.2015.01056","volume":"9","author":"M Meng","year":"2015","unstructured":"Meng, M. et al. Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma. Drug Discov Ther. 9(5), 372\u2013379 (2015).","journal-title":"Drug Discov Ther."},{"key":"BFsrep37987_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","volume":"76","author":"L Potters","year":"2010","unstructured":"Potters, L. et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int. J Radiat Oncol Biol Phys. 76(2), 326\u2013332 (2010).","journal-title":"Int. J Radiat Oncol Biol Phys"},{"key":"BFsrep37987_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clon.2009.12.003","volume":"22","author":"A Martin","year":"2010","unstructured":"Martin, A. & Gaya, A. Stereotactic body radiotherapy: a review. Clin Oncol (R Coll Radiol). 22(3), 157\u2013172 (2010).","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFsrep37987_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000322423","volume":"43","author":"S Dieterich","year":"2011","unstructured":"Dieterich, S. & Gibbs, I. C. The CyberKnife in clinical use: current roles, future expectations. Front Radiat Ther Oncol. 43, 181\u2013194 (2011).","journal-title":"Front Radiat Ther Oncol"},{"key":"BFsrep37987_CR11","doi-asserted-by":"crossref","first-page":"15690","DOI":"10.18632\/oncotarget.3704","volume":"6","author":"MB Meng","year":"2015","unstructured":"Meng, M. B. et al. Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget. 6(17), 15690\u201315703 (2015).","journal-title":"Oncotarget"},{"key":"BFsrep37987_CR12","doi-asserted-by":"publisher","first-page":"8156","DOI":"10.3748\/wjg.v21.i26.8156","volume":"21","author":"TS Su","year":"2015","unstructured":"Su, T. S. et al. Stereotactic body radiotherapy using CyberKnifer for locally advanced unresectable and metastatic pancreatic cancer. World J Gastroenterol. 21(26), 8156\u20138162 (2015).","journal-title":"World J Gastroenterol"},{"key":"BFsrep37987_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jso.23858","volume":"111","author":"N Dagoglu","year":"2015","unstructured":"Dagoglu, N. et al. Stereotactic body radiotherapy (SBRT) reirradiation for pelvic recurrence from colorectal cancer. J. Surg Oncol. 111(4), 478\u2013482 (2015).","journal-title":"J. Surg Oncol."},{"key":"BFsrep37987_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","volume":"69","author":"P Ost","year":"2016","unstructured":"Ost, P. et al. Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis. Eur Urol. 69(1), 9\u201312 (2016).","journal-title":"Eur Urol."},{"key":"BFsrep37987_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1748-717X-7-164","volume":"7","author":"I Fumagalli","year":"2012","unstructured":"Fumagalli, I. et al. A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol. 7, 164 (2012).","journal-title":"Radiat Oncol."},{"key":"BFsrep37987_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2147\/OTT.S58409","volume":"7","author":"ZY Yuan","year":"2014","unstructured":"Yuan, Z. Y. et al. Stereotactic body radiation therapy using the Cyberknife (\u00ae) system for patients with liver metastases. Onco Targets Ther. 7, 915\u2013923 (2014).","journal-title":"Onco Targets Ther."},{"key":"BFsrep37987_CR17","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee, M. T. et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 27(10), 1585\u20131591 (2009).","journal-title":"J Clin Oncol"},{"key":"BFsrep37987_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10549-008-0157-4","volume":"115","author":"MT Milano","year":"2009","unstructured":"Milano, M. T. et al. Oligometastatic breast cancer treated with curative intent stereotactic body radiation therapy. Breast Cancer Res Treat 115, 601\u2013608 (2009).","journal-title":"Breast Cancer Res Treat"},{"key":"BFsrep37987_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.radonc.2011.05.033","volume":"101","author":"A Takeda","year":"2011","unstructured":"Takeda, A. et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 101(2), 255\u2013259 (2011).","journal-title":"Radiother Oncol."},{"key":"BFsrep37987_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/153303460700600412","volume":"6","author":"BS The","year":"2007","unstructured":"The, B. S. et al. Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy (SBRT) for various anatomical sites. Technol Cancer Res Treat. 6(4), 347\u201354 (2007).","journal-title":"Technol Cancer Res Treat"},{"key":"BFsrep37987_CR21","unstructured":"Common terminology criteria for adverse events (CTCAE), version 4.0. http:\/\/www.acrin.org\/Portals\/0\/Administration\/Regulatory\/CTCAE_4.02_200909-15_QuickReference_5x7.pdf (2014)."},{"key":"BFsrep37987_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ejca.2008.10.027","volume":"45","author":"J Bogaerts","year":"2009","unstructured":"Bogaerts, J. et al. RECIST Working Party RECIST Working Party: Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer. 45(2), 248\u2013260 (2009).","journal-title":"Eur J Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37987","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:06:08Z","timestamp":1672880768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,29]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37987"],"URL":"https:\/\/doi.org\/10.1038\/srep37987","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,29]]},"assertion":[{"value":"26 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37987"}}